Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Adverse effects ‐ complication rate at 1 week after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in adverse effects ‐ complication rate at 1 week after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Adverse effects ‐ complication rate at 3 months after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in adverse effects ‐ complication rate at 3 months after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Recurrence after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in recurrence rate at 3 months after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
1 finding from 1 review
Oral mucositis (moderate to severe). Not estimable - no participants had developed moderate or severe oral mucositis by the fourth day after chemotherapy when the data were reported (Zhang 2011, Analysis 4.2, subgroup…
1 study · 81 participants
GRADE not reported
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).
1 finding from 1 review
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review
Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review
Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
1 study · 424 participants
GRADE not reported
Patient satisfaction · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Treatment costs · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
The review found no eligible studies for this question.
1 finding from 1 review
Treatment costs: no trials reported this outcome (extrapolated by the review authors). Additional costs were associated with the long-implant + augmentation group (extra surgery, biomaterial, barrier, hospitalisation…
0 studies
No studies found
Patient preference · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Complications (at treated sites) · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants may leads to higher complications (at treated sites) compared with short implants (5 to 8.5 mm) without sinus augmentation (low certainty).
1 finding from 1 review
Augmentation procedure failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
1 finding from 1 review
Implant failure · Patients with missing teeth and an atrophic posterior maxilla, with residual bone height between 4 and 9 mm below the maxillary sinus
Maxillary sinus lift (augmentation) with long implants showed no clear difference in implant failure compared with short implants (5 to 8.5 mm) without sinus augmentation (moderate certainty).
1 finding from 1 review
Implant failure · Patients undergoing one-stage crestal maxillary sinus lift without bone grafts (baseline residual bone height about 6.5 mm)
Hand mallet (osteotomes) showed no clear difference in implant failure compared with electric mallet; GRADE not reported.
1 finding from 1 review
Augmentation procedure failure · Patients undergoing one-stage crestal maxillary sinus lift without bone grafts (baseline residual bone height about 6.5 mm)
1 finding from 1 review
Primary outcome: Histological complete response ( available‐case analysis) No residual LM in staged excision 2 months post‐treatment · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in primary outcome: Histological complete response (intention‐to‐treat)… compared with imiquimod 5% cream alone (low certainty).
2 findings from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3) Grade 2 or 3 Inflammation² · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel may leads to higher secondary outcome: Inflammatory response (number of lesions with… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review